Aigen Investment Management LP Takes $338,000 Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Aigen Investment Management LP purchased a new position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) in the fourth quarter, HoldingsChannel reports. The institutional investor purchased 10,994 shares of the specialty pharmaceutical company’s stock, valued at approximately $338,000.

Several other large investors have also recently added to or reduced their stakes in the stock. Pacer Advisors Inc. boosted its holdings in Collegium Pharmaceutical by 68.4% in the 4th quarter. Pacer Advisors Inc. now owns 2,174,718 shares of the specialty pharmaceutical company’s stock worth $66,938,000 after acquiring an additional 883,380 shares during the period. BNP Paribas Financial Markets lifted its stake in shares of Collegium Pharmaceutical by 119.6% in the fourth quarter. BNP Paribas Financial Markets now owns 146,543 shares of the specialty pharmaceutical company’s stock worth $4,511,000 after acquiring an additional 79,823 shares in the last quarter. SummerHaven Investment Management LLC grew its stake in Collegium Pharmaceutical by 1.1% during the 4th quarter. SummerHaven Investment Management LLC now owns 34,034 shares of the specialty pharmaceutical company’s stock valued at $1,048,000 after purchasing an additional 368 shares in the last quarter. Johnson Investment Counsel Inc. purchased a new stake in Collegium Pharmaceutical during the 4th quarter worth approximately $257,000. Finally, Natixis Advisors L.P. raised its position in shares of Collegium Pharmaceutical by 152.9% in the 3rd quarter. Natixis Advisors L.P. now owns 54,359 shares of the specialty pharmaceutical company’s stock valued at $1,215,000 after purchasing an additional 32,865 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the stock. StockNews.com lowered shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, May 1st. Piper Sandler downgraded Collegium Pharmaceutical from an “overweight” rating to a “neutral” rating and set a $39.00 price objective for the company. in a research report on Friday, May 10th. Truist Financial raised their target price on Collegium Pharmaceutical from $37.00 to $40.00 and gave the company a “buy” rating in a research report on Monday, February 26th. Finally, Needham & Company LLC cut Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Friday, May 10th. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $39.00.

Collegium Pharmaceutical Price Performance

Shares of Collegium Pharmaceutical stock traded up $0.43 during trading on Friday, hitting $34.25. The stock had a trading volume of 320,990 shares, compared to its average volume of 506,732. The business has a fifty day moving average of $36.74 and a two-hundred day moving average of $33.11. The firm has a market cap of $1.12 billion, a P/E ratio of 14.27 and a beta of 1.06. Collegium Pharmaceutical, Inc. has a fifty-two week low of $20.83 and a fifty-two week high of $40.95. The company has a debt-to-equity ratio of 1.98, a current ratio of 1.21 and a quick ratio of 1.14.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings results on Thursday, February 22nd. The specialty pharmaceutical company reported $1.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.20 by $0.25. The company had revenue of $149.75 million for the quarter, compared to analysts’ expectations of $147.66 million. Collegium Pharmaceutical had a return on equity of 104.98% and a net margin of 16.46%. On average, sell-side analysts expect that Collegium Pharmaceutical, Inc. will post 5.63 earnings per share for the current fiscal year.

Insider Transactions at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, Director Garen G. Bohlin sold 28,985 shares of the firm’s stock in a transaction dated Tuesday, May 14th. The shares were sold at an average price of $32.30, for a total value of $936,215.50. Following the completion of the transaction, the director now directly owns 44,775 shares in the company, valued at $1,446,232.50. The sale was disclosed in a filing with the SEC, which is accessible through this link. 3.98% of the stock is owned by insiders.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.